Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajem.2022.07.013 | DOI Listing |
J Antimicrob Chemother
October 2024
Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Unlabelled: Staphylococcus aureus (SA) is a leading cause of bloodstream infection. The liver represents the sentinel immune organ for clearance of bloodstream pathogens and eradication of intracellular SA from liver-resident macrophages (Kupffer cells, KCs) eliminates the likely pathogenic reservoir that contributes to persistent bacteraemia.
Objectives: We assessed antimicrobial activity at phagolysosome-mimicking pH, intracellular penetration, and SA eradication within KCs in vitro for clinically prescribed antistaphylococcal agents alone or in combination: vancomycin, daptomycin, ceftaroline, ceftobiprole, oritavancin, oxacillin, cefazolin; rifampin and fosfomycin.
Ann Clin Microbiol Antimicrob
July 2024
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Background: Gram-negative bacteria (GNB) are becoming increasingly resistant to a wide variety of antibiotics. There are currently limited treatments for GNB, and the combination of antibiotics with complementary mechanisms has been reported to be a feasible strategy for treating GNB infection. The inability to cross the GNB outer membrane (OM) is an important reason that a broad spectrum of Gram-positive only class of antibiotics (GPOAs) is lacking.
View Article and Find Full Text PDFInfect Dis Ther
March 2024
Melinta Therapeutics, Medical Affairs, Parsippany-Troy Hills, USA.
Infez Med
December 2023
Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction: The increasing emergence of bacterial strains with new resistance determinants has become a threat to current antibiotic therapies in recent years. This has prompted research for innovative options with improved efficacy and safety profiles: long-acting glycopeptides, such as dalbavancin and oritavancin, are currently approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Their efficacy, microbiological profile, and ease of administration may provide an answer to this challenge, as well as reducing length of stay and hospital costs.
View Article and Find Full Text PDFClin Microbiol Infect
August 2023
Institute for Infectious Diseases, University of Bern, Bern, Switzerland. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!